ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10026
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd (IMUC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
Licensing Agreements 19
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
Equity Offering 23
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd – Key Competitors 34
ImmunoCellular Therapeutics Ltd – Key Employees 35
ImmunoCellular Therapeutics Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Aug 13, 2018: ImmunoCellular Therapeutics provides corporate update and reports second quarter 2018 financial results 37
May 14, 2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results 39
Mar 13, 2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 40
Nov 21, 2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results 41
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 42
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 43
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 44
Product News 46
12/13/2017: ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 46
Apr 12, 2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 47
Other Significant Developments 48
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition 48
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd, Key Competitors 34
ImmunoCellular Therapeutics Ltd, Key Employees 35
ImmunoCellular Therapeutics Ltd, Subsidiaries 36
ImmunoCellular Therapeutics Ltd, Joint Venture 36

List of Figures
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Laboratorios Liomont SA de CV-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorios Liomont SA de CV (Liomont) is a healthcare products provider that offers research and develops medicines for medication, prescription and OTC markets. The company offers prescription medication products and over the counter products. It offers drugs in serves various therapeutic …
  • El Paso Electric Company:企業の発電所・SWOT分析2018
    El Paso Electric Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Arrowhead Pharmaceuticals Inc (ARWR):企業の財務・戦略的SWOT分析
    Summary Arrowhead Pharmaceuticals Inc (Arrowhead), formerly known as Arrowhead Research Corp, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and AR …
  • FRONTEO, Inc. (2158):企業の財務・戦略的SWOT分析
    FRONTEO, Inc. (2158) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Rigaku Corporation:企業の戦略・SWOT・財務情報
    Rigaku Corporation - Strategy, SWOT and Corporate Finance Report Summary Rigaku Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Wien Energie GmbH:企業の戦略的SWOT分析
    Wien Energie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Sharp HealthCare:企業の戦略的SWOT分析
    Sharp HealthCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Spire Inc (SR):企業の財務・戦略的SWOT分析
    Spire Inc (SR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Frontier Oilfield Services Inc (FOSI):石油・ガス:M&Aディール及び事業提携情報
    Summary Frontier Oilfield Services Inc (FOS) is an oil and gas company that provides drilling fluid disposal and saltwater recovery services. The company offers oilfield services such as well schematic and saltwater disposal, saltwater disposal and recovery services. Its saltwater disposal and recov …
  • Ircon International Limited:企業の戦略・SWOT・財務情報
    Ircon International Limited - Strategy, SWOT and Corporate Finance Report Summary Ircon International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Great Basin Scientific Inc (GBSN):製品パイプライン分析
    Summary Great Basin Scientific Inc (Great Basin) is a molecular diagnostics company that offers technology products. The company develops and distributes point-of-care technology and products to improve automation, throughput, scalability, reliability and ease-of-use in rapid diagnostic testing. It …
  • Florida Hospital:製薬・医療:M&Aディール及び事業提携情報
    Summary Florida Hospital is a healthcare service provider. The hospital offers clinical services and treatments in the areas of bariatric, behavioral health, cancer, cardiovascular, diabetes, emergency services, gastrointestinal, general surgery, gynecology, hepatology, imaging, laboratory services, …
  • Biocept Inc (BIOC):製薬・医療:M&Aディール及び事業提携情報
    Summary Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell l …
  • Forty Seven Inc (FTSV):製薬・医療:M&Aディール及び事業提携情報
    Summary Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cardiac Dimensions Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardiac Dimensions Inc (Cardiac Dimensions) is a medical equipment company that develops intervention tools used for treating heart failure and other related cardiovascular conditions. The company develops carillon mitral contour system, a coronary sinus-based percutaneous mitral annuloplast …
  • Covalon Technologies Ltd (COV):製品パイプライン分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • The National Petrochemical Co:企業の戦略的SWOT分析
    The National Petrochemical Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Vapo Oy:企業の戦略的SWOT分析
    Vapo Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • MyoKardia Inc (MYOK):製薬・医療:M&Aディール及び事業提携情報
    Summary MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company's pipeline products include therapeutic programs for the treatment …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆